No formula can value a company with no revenue. Work backwards from the raise, the investor's return math and honest comparables, then pressure-test the number before you negotiate.
Most founders arrive at their first valuation conversation holding a number they cannot explain. It may come from a headline about another startup, a friend's round, or a hopeful guess about what the company will one day be worth. Then an investor asks how they got there, and the answer falls apart, because there was never a calculation behind it. There could not have been one.
A company with no revenue has no earnings to multiply, no cash flows to discount with any confidence and no track record to extrapolate. What it has is a plan, a team and some early evidence. Turning those into a defensible price means working backwards from three constraints: the money the round must raise, the ownership an investor needs to earn a worthwhile return, and the prices at which similar early deals have actually closed. Then you test what happens if the number is pushed too high.
Why no formula settles it
Valuation methods for mature companies rest on something observable. A business with steady earnings can be valued by applying a multiple that similar businesses trade at, and one with predictable cash flows by estimating those flows and discounting them to today. Both turn the past into a view of the future. A pre-revenue company has no past to turn, so every input is itself a guess about the future. Change the assumed market share, growth rate or discount rate slightly and the output moves enormously, which is why two analysts can value the same company at wildly different levels and both be internally consistent. Such a model can be a rough cross-check, but it cannot anchor a negotiation, because neither side can verify the inputs.
What fills the gap is a negotiation between two parties with different constraints. The founder needs a certain amount of money and does not want to give up more of the company than necessary. The investor needs to own enough of the company, after future dilution, to justify a risky bet. A realistic valuation sits where those constraints overlap and where comparable deals suggest the market will agree. Your job is to find that overlap before you walk into the room, rather than discovering it halfway through a term sheet discussion.
Start from what the round must fund
The first constraint is the one you control entirely. Before thinking about price, decide what the money has to accomplish. A round should buy a specific, evidence-based milestone: a working product with paying pilot customers, a regulatory approval, a manufacturing run, validated unit economics. The milestone fixes two things at once: how much you need to raise, and what the next investor will want to see before writing a larger check.
To size the raise, build a month-by-month plan from today to that milestone covering salaries, contractors, tooling, legal costs and any equipment or inventory. Add a buffer, because early plans almost always run late and cost more than expected, then convert the total into months of runway. The guide on how founders calculate their startup's runway before raising capital walks through this. A common error is to raise enough to reach the milestone but not enough to survive the fundraising that follows it, which can take longer than the building itself, as discussed in why raising money can take longer than building the product.
A worked hypothetical
Consider a hypothetical founder building software that helps small clinics manage supply orders. She has a prototype, three clinics willing to pilot it and no revenue. Her plan says that reaching twenty paying clinics with repeatable monthly usage will take eighteen months and cost $900,000, buffer included. She wants six more months of cushion for the next raise, so she decides to raise $1.2 million. These figures are invented for illustration and are not benchmarks.
Now she can see what each valuation costs her. Ownership sold equals the amount raised divided by the post-money valuation, which is the pre-money valuation plus the new money. The table shows what $1.2 million costs at several pre-money valuations.
| Pre-money valuation | Post-money valuation | Ownership sold | Founder share before option pool |
|---|---|---|---|
| $3.0 million | $4.2 million | About 28.6% | About 71.4% |
| $4.0 million | $5.2 million | About 23.1% | About 76.9% |
| $6.0 million | $7.2 million | About 16.7% | About 83.3% |
| $8.0 million | $9.2 million | About 13.0% | About 87.0% |
The table does not say which number is right. It shows the trade she is making: moving from $3 million to $6 million roughly halves the ownership she gives up. Whether any investor will accept the higher figure, and what it costs her if one does, are the questions the next two sections answer.
One adjustment matters before moving on. Many investors expect a new option pool for future hires to be created inside the pre-money valuation, so the dilution falls on existing holders rather than on the new investor. If the investor asks for a pool equal to ten percent of the company after the round, the founder's effective pre-money value is lower than the headline, because shares reserved for future employees are carved out of her side of the deal. Always ask whether a quoted valuation is before or after the pool is created.
Think like the investor
The second constraint belongs to the investor, and understanding it explains why they rarely pay what founders hope. A venture investor is not buying a business at a fair price. They are buying a small chance at a very large outcome, knowing most of their bets will fail. In a portfolio of early-stage companies, a few winners typically have to pay for many that return little or nothing. So each company they choose must have a credible path to a multiple of the money invested, not just a modest gain. That target is not a forecast or a promise. It is the hurdle a company must plausibly clear for the investor to take the risk at all.
Working the investor's math in reverse
Investors often reason backwards from a successful exit. Suppose the investor in our hypothetical believes that, if the clinic software works, the company could plausibly be sold for $60 million after several more years, and that their target is a tenfold return on a successful outcome. Investing $1.2 million and wanting $12 million back from a $60 million sale means they must own 20% at the moment of exit, not at the moment of investment.
Later dilution is what changes the price. The company will probably raise more rounds before any sale, and each round issues new shares that reduce every earlier holder's percentage. If the investor expects to be diluted by half, they must buy about 40% today to hold 20% at the end. Forty percent for $1.2 million implies a post-money valuation of $3 million and therefore a pre-money of $1.8 million. The founder who hoped for $6 million has met a very different number, and neither side has been unreasonable. The assumptions are hypothetical, but the mechanism is real: the more dilution an investor expects and the higher the multiple they require, the less they can pay now.
The same arithmetic shows which levers actually move price. A larger plausible exit, lower perceived failure risk or less expected future dilution each lets the investor pay more today. Evidence that the market is large, that customers will pay and that you can reach the next milestone cheaply does not change a formula; it changes the investor's belief about those inputs. That is the real work of the pitch, and why guidance on building investor confidence without revenue or a track record bears directly on price.
Use comparables without fooling yourself
The third constraint is the market's memory. Investors and founders both look at what similar companies raised at, and those reference points anchor expectations. Used honestly, comparables show the range in which deals actually close. Used carelessly, they let a founder pick the one flattering deal and call it the market. The way to avoid that is to match the dimensions that genuinely move price.
Stage comes first: a company with an idea is priced differently from one with a working product and pilot users. Sector matters because capital intensity, timelines and exit sizes differ between hardware, software and regulated health businesses. Geography matters because the pool of local capital, the size of reachable markets and the likelihood of a large exit vary by region, and an investor who must convert currency or accept local exit constraints will price that in.
Investor type is the dimension founders most often ignore. An angel investing personal money can accept a smaller outcome and may price on belief in the founder. A venture fund needs the company to return a meaningful part of the fund, so it insists on larger potential and tougher math. An accelerator typically offers a small amount of money for a fixed stake in exchange for a program and network, so the price is a package rather than a negotiated valuation. Grant makers take no equity, and revenue-linked providers price against expected repayments rather than ownership. Comparing a venture price to an accelerator's, or to a grant, tells you little. For how these capital types differ, see the founder's guide to choosing the right funding path.
Borrowed benchmarks also have limits. Published or rumored figures are a biased sample, since well-publicized rounds are visible and quiet, lower-priced ones are not. A comparable is also a snapshot of a market mood, and valuations drift with the availability of capital. And the company you are comparing to may have had something you cannot see, such as a founder with a prior exit or unusual early traction. Treat comparables as a range and a sanity check, ideally gathered from advisers, other founders and investors who have seen several deals, never as a single number to copy.
Count the cost of a high number
Once the constraints have narrowed the range, it is tempting to push to the top of it, or past it, on the theory that a higher valuation is always better for the founder. It is not, because the price you set today becomes the bar the next investor must clear.
Suppose our hypothetical founder secures a $10 million pre-money valuation on the strength of enthusiasm. Eighteen months later she has hit the milestone, but progress was slower than hoped and the market is more cautious. The next investor, applying the same return math, thinks the company is worth $6 million. She now faces a down round, in which new shares are issued at a lower price than before. That cuts her ownership more sharply, may trigger anti-dilution protections that adjust earlier investors' terms in their favor, and signals to employees, customers and later investors that the company has stumbled. Some founders in that position struggle to raise at all.
Structure can also quietly undo a headline number. An investor who agrees to a high valuation may ask for protective terms in return, such as a liquidation preference that pays them first when the company is sold, or participation rights that let them take their money back and still share in the remainder. A founder who wins the price and loses on the terms may be worse off than one who accepted a lower valuation on clean terms. The post on founder-friendly versus investor-protective term sheets sets out these trade-offs, and what selling 20% really means shows why the percentage alone says little.
When a convertible defers the question
Sometimes the honest answer is that nobody can price the company yet. A SAFE or convertible note takes the investor's money now and converts it into equity at a later priced round, usually at a discount to that round's price or subject to a valuation cap that limits the conversion price. The valuation conversation waits until there is more evidence and a lead investor to set the price.
That is useful when the round is small, speed matters or the company is too early for a meaningful price. But it is a deferral, not an escape. The cap is a valuation in disguise, and investors will read it as one. Several instruments with generous caps can stack up and convert into a larger share of the company than the founder expected, so model the conversion before you sign. Terms and legal treatment vary by jurisdiction, and notes carry debt features such as a maturity date, so take legal advice on which fits your situation.
Pressure-test the number
Before you negotiate, run your proposed valuation through the checks an investor will apply. These are separate tests, so a short checklist fits.
- Does the raise reach the milestone? Confirm the amount covers the plan, a buffer and the time needed to raise again.
- Is the dilution acceptable? Model your ownership after this round, a likely next round and an option pool, and check that you and the team still hold enough to stay motivated.
- Does the investor's math work? Estimate a plausible successful exit, the dilution to come and a target multiple, and see what ownership they would need. If your price means they could not hit their target even in a good outcome, expect resistance.
- Do honest comparables support it? Match stage, sector, geography and investor type, and look for deals that did not make headlines.
- What happens if you miss? Ask what the next investor would pay if you reach only most of the milestone. If the answer is below today's price, you are exposed to a down round.
- Which terms come with it? Compare offers on the whole package, not only the headline valuation.
Run these tests on several valuations rather than one, to produce a range: a number you would be pleased with, one you would accept, and one below which you would walk away or switch to a convertible. Having that range written down before the first call stops you anchoring on the first figure an investor mentions. The startup valuation calculator can help sanity-check your inputs, though the reasoning above matters more than any single output. Talking to founders who have raised at your stage, and advisers who have seen many term sheets, shows where real deals land.
If you are preparing a raise, Fundverse can help you organize the evidence an investor will test your valuation against, from a clean data room to investor matching that fits your stage and sector. Use it to get ready for the conversation, not to replace your own judgment about the price.
A fair price is one you can grow into
The temptation in a valuation negotiation is to treat the number as a score, as though a higher figure meant a better company or a better founder. It means neither. It is the price at which two parties with different constraints agreed to share risk, and its main job is to leave the company able to raise again on better terms.
So choose the number you can defend backwards: from the milestone the money buys, from the return the investor needs, and from the deals that have really closed around you. A price you can grow into leaves room for the next investor to say yes. A price you must hope the market eventually justifies leaves you negotiating from a weaker position at the moment you can least afford it.
Frequently asked questions
Topics
pre-revenue valuation
startup valuation no revenue
how to value a startup
seed round dilution
SAFE valuation cap
down round risk
investor target return
valuation comparables
Raising or investing?
Find the right people on the other side of the table, and run the round in one place.

